{
    "nctId": "NCT02553850",
    "briefTitle": "An Observational Study in Patients With Breast Cancer and Bone Metastases Receiving Ibandronate (Bondronat)",
    "officialTitle": "A SURVEY TO STUDY THE CORRELATION BETWEEN THE SERUM LEVELS OF BONE TURNOVER MARKERS AND THE CLINICAL PICTURE IN PATIENTS WITH BREAST CANCER AND BONE METASTASES RECEIVING IBRADONIC ACID TREATMENT",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 442,
    "primaryOutcomeMeasure": "Beta C-terminal telopeptide (B-CTx) level",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All criteria in accordance with the Summary of Product Characteristics of Bondronat (ibandronate)\n* Adult patients greater than (\\>) 18 years of age\n* Histologically confirmed breast cancer\n* Confirmed bone metastasis (by bone scintigraphy, X-ray, computed tomography or magnetic resonance imaging)\n* Life expectancy \\>6 months\n* No previous bisphosphonate therapy\n* Patients signed written informed consent form before study start\n\nExclusion Criteria:\n\n* All criteria in accordance with the Summary of Product Characteristics of Bondronat(ibandronate)\n* Hypersensitivity to the active substance or any of the excipients of Bondronat (ibandronate)\n* Hypersensitivity to bisphosphonates",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}